RASAMEEL

GLOBAL EQUITIES STRATEGY

FACT SHEET

30/04/2023

Investment Objective
The Strategy invests in Sharia compliant equities across the major markets, with the objective of generating returns in excess of the benchmark, over a 3-5 year period.

Investment Manager
Rasameel Investment Company KSCC

Time Horizon
Longterm

Inception Date
01/11/2016

Base Currency
USD

Benchmark Index
MSCI World Islamic index

Top Holdings

Company	Weight
MRK US	3.2%
META US	3.1%
NOVN SW	2.8%
AZN LN	2.6%
YCA LN	2.6%

Characteristics	Strategy
TTM P/E	15.45
P/B	2.50
P/CF	10.78
Dividend Yield	2.7%
Debt/Equity	0.47

Returns	Strategy (Gross)	Benchmark (Net)
MTD	1.2%	1.4%
YTD	6.3%	10.4%
ITD	63.5%	70.0%

Risk Statistics - 1Yr	Strategy	Benchmark
Std. Dev	15.8%	18.6%
Downside Risk	11.4%	13.2%
MC VAR	25.2%	28.0%
BETA (ex-post)	0.80	1.00
Correlation	0.94	1.00
Sharpe Ratio	0.01	0.2
IR	-0.44	NA

Performance



Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	YTD	Benchmark
2023(%)	5.3	-4.1	3.9	1.2									6.3	10.4
2022 (%)	-1.6	0.5	1.5	-5.9	0.8	-6.1	2.2	-0.8	-8.1	4.3	6.6	-1.7	-9.1	-11.7
2021 (%)	1.0	4.1	0.8	0.7	2.2	-0.8	-3.2	-2.7	-4.1	5.4	-2.3	2.6	3.6	21.9
2020 (%)	-2.8	-5.5	-6.8	8.1	6.0	3.8	6.1	2.1	-3.8	0.1	7.1	6.2	21.1	7.8
2019 (%)	9.6	3.6	-0.6	7.6	-10.3	7.1	0.6	-1.1	-0.5	2.7	2.6	4.4	26.9	22.1
2018 (%)	6.6	-3.6	-3.1	1.5	0.9	-0.9	0.8	0.3	-2.7	-9.5	-3.1	-6.4	-18.1	-9.9
2017 (%)	0.9	3.5	3.6	0.9	0.8	-0.9	1.8	1.8	4.5	2.1	2.5	1.2	23.9	19.1
2016 (%)											0.7	3.1	3.8	3.6

30 Day Top Contributers & Detractors

Contributers	Return	Cont.	Detractors	Return	Cont.
META US	13.4%	0.4%	GFS US	-18.5%	-0.3%
NOVN SW	11.7%	0.3%	9618 HK	-19.8%	-0.3%
MRK US	8.5%	0.3%	CRWD US	-12.5%	-0.2%
ROG SW	10.3%	0.2%	ZM US	-16.8%	-0.2%
AEM US	11.3%	0.2%	NTR US	-6.0%	-0.1%

Geographic Breakdown



Sector Breakdown



* *The performance shown above is gross of all fees and unaudited. Past performance is not indicative of future returns.*

Disclaimer:

This document is prepared for promotional purposes. The performance stated above is for a composite of client accounts and is gross of all fees and commissions. Actual client performance may vary from the composite. Rasameel Investment Company hereby undertakes that it does not disguise, diminish or obscure important items from the investment subject of promotion.

Warning:

The past performance of any investment or a product is not a reliable indicator of future results and it cannot be relied upon for investment decision making.

Commentary

The Global strategy returned 1.2% for the month. Macro indicators came in mixed for the month, while earnings were better-than-expected but are still in decline. We expect they will decline further into the 2h23 and '24. Expectations that the May rate hike will be the last are increasing as investors believe the Fed is nearing the end to its' rate hiking cycles. What is unknown is how long the Fed and other central banks will main these high rates.

In April 2023, the United States witnessed a mixed bag of economic indicators. In retail sales, there was a decline across various categories, with retail sales excluding automobiles and fuel experiencing a decrease of 0.31%. Similarly, overall retail sales saw a decline of 1.0%. These figures suggest a dip in consumer spending during the period. Additionally, the ADP Employment Survey reported a lower-than-expected figure of 145,000 new jobs added in March. In terms of inflation, the Consumer Price Index (CPI) excluding food and energy rose by 0.40%, meeting expectations. However, the overall CPI increased by 5.0% year-on-year, below the consensus estimate of 5.2%.

During the month, **Meta Platforms (META US)** emerged as one of the top contributors to the portfolio. The company's second-quarter revenue forecast exceeded analysts' expectations, driven by cost reductions, improving revenue trends, and investments in artificial intelligence. Meta Platforms reported strong first-quarter results, surpassing revenue estimates, with advertising revenue as the primary growth driver. In the healthcare sector, **Merck & Co.** delivered impressive Q1 earnings, surpassing expectations. The remarkable growth of its immunotherapy cancer drug, Keytruda, played a significant role in exceeding analyst estimates. Merck raised its full-year guidance, emphasizing its focus on expanding the pipeline of autoimmune drugs.

On the other hand, **GlobalFoundries** was the top detractor for the month. The company experienced a significant drop, even more pronounced than the weakness observed in the SOXX index, which was influenced by peer earnings. Adding to the negative sentiment, GlobalFoundries filed a lawsuit against IBM, alleging the sharing of patents with Intel. In the e-commerce sector, **JD.com** witnessed a decline in its shares due to various factors. The company's business adjustments and major organizational restructuring introduced limited visibility for the coming quarters, resulting in short-term disruptions. Additionally, proposed regulations by Chinese authorities to control AI technology, competition from rivals, and a slow recovery from the pandemic recession led to estimate cuts and weakened investor sentiment towards JD.com. We do though continue to like the stock long term and the company has significant cash to do share buybacks and the like. Something, we would advocate at the current share price. **Zoom Video Communications** experienced a downturn as concerns about the company's growth rates weighed on investor confidence. Weaker spending intentions on videoconferencing by companies and rising competition posed risks to customer renewals. However, the acquisition of Workvivo was viewed positively as a potential contributor to revenue growth and long-term significance.

In our Outlook for 2023 report, we took the view that 2H23 would likely be an opportune time 'to add' to equities. We maintain this view and continue to expect equities to come under pressure due to weaker earnings. This hasn't yet played out. The market is not cheap, with the S&P500 trading at 18x. With rates at 5%, we have already witnessed tight policies putting pressure on many financials with SVB, Signature, Credit Swiss and now First Republic all coming under pressure. Without the Fed and Treasury providing support to the banks, the fallout would have been significantly worse. A bank run is what led to the 1929 collapse. While we remain cautious overall, we are not expecting a sell-off like 2000 or 2009, for two key reasons. The epicenter of the current slowdown is in the small to mid-sized banking space. The health of this segment is key to the loan market to SMEs and the like; hence the Fed and Treasury will do all in their power to protect it from contagion. Secondly, the Fed and Treasury appear to be no longer shackled in terms of the scale of their operations. We saw this very recently with them stepping in aggressively to support SVB deposits. We expect to see more of the same. We would also note that economists are generally very bearish, and that the slowdown is expected by most market commentors and will thus be positioned for it. Given all this, we have marginally adjusted our equity exposure and have very marginally rotated out of Energy and into more growth orientated exposures. We look forward to adding aggressively to equity exposure once we have seen earnings contractions being more fully priced in.

GLOBAL EQUITIES STRATEGY

FACT SHEET

30/04/2023

Strategy Top Holdings

STOCK	INVESTMENT THESIS	
		Fundamental Investment Thesis
MERCK	**Rationale**	Merck & Co., Inc. is a top 5 holding in the strategy. Merck is a large-cap pharmaceutical company with a deep heritage in drug discovery. We are bullish on the continued growth of key asset Keytruda, the leading immune oncology agent used to treat a variety of cancers. We retain long-term conviction as we expect Keytruda to solidify its position. Merck's robust top-line growth should more than support its pipeline, including 8 new potential drugs by 2030. Merck sports a very strong credit rating, pays a solid and growing dividend yield, and is trading well below a 15 PE.
YELLOW CAKE	**Rationale**	We like Uranium as it is the greenest and most reliable source of energy on the planet. With years of underinvestment in uranium supply, and demand starting to rise from China, India, and Japan, we expect uranium prices to rise much higher. Yellow Cake is our investment vehicle of choice, as it provides physical storage of uranium oxide and is currently trading at a discount around 25% to its Net Asset Value, essentially buying physical uranium at a discount. Yellow Cake is likely to trade at a premium as prices start to rise again.
AMGEN	**Rationale**	As a big-cap biotech, Amgen has offered great relative performance as the company is growing revenue 70% in 3 years. This has been made possible by the offerings and the continued success the company sees in getting approvals for their drug readouts.
NOVN SW	**Rationale**	Novartis is a multinational pharmaceutical corporation. Generating strong cashflow and continuously attempts to improve its pipeline. Valuation is attractive. With high cash flow and the selling its generic arm Sandoz, it will continue its growth through acquisitions and strong pipeline.
JD.COM	**Rationale**	We see JD.com as an attractive "Quality China Internet Growth" play and one of the most attractive ways to get exposure to Chinese retail, where ecommerce penetration continues to grow. Expansion outside of China could increase JD's TAM further. The company is well positioned to improve its market share gains within the Chinese e-commerce sector. We expect 2H2022 business re-acceleration, 618 Shopping festival, OPM stability and continuing market share gains from peers to be key near-term catalysts. In addition, greater monetary easing by China in 2H2022, progress on audit cooperation with SEC, and ADR delisting fears subsiding could significantly improve investor sentiment for China internet sector companies and JD.com in particular.

Strategy vs Peers

GLOBAL EQUITIES STRATEGY - YTD PERFORMANCE VS SIMILAR STRATEGIES



Reported numbers as of 30 April 2023